Bringing the fundamentals into focus…
Back to Monte Rosa Therapeutics, Inc.
How Monte Rosa Therapeutics, Inc. stacks up
GLUE · against 440 other Healthcare companies of similar size
Growth
3/ 100
Near the bottom of its peers.
Ranked #423 of 441 · scores higher than 3% of peers
Bars: peers in each 10-point band of the growth score43 peers with a growth score of 0–9, including GLUE · Click a bar to see the companies
Why growth scores 3?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth and earnings per share growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 98% of peers. Revenue growth: -83.9% vs peer median 6.1%
- Earnings per share turned from a profit to a loss. Earnings per share growth: — vs peer median 9.8%
- 3-year revenue growth is not reported, so it is left out of the score.
Metric by metric
Position: dot = GLUE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | GLUE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 449 reported | -83.9% | 4.1% | 2% | 33% | |
| Earnings per share growthHigher is better · 239 reported | Not reported | 5.0% | — | — | 33% |
| 3-year revenue growthHigher is better · 435 reported | Not reported | 4.9% | — | — | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around GLUE| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 885M USD | 99 | 33 | |
| 2 | 609M USD | 99 | 91 | |
| 421 | 6.0B CNY (≈$841M) | 4 | 29 | |
| 423 | 3.4B CNY (≈$469M) | 3 | 42 | |
| 423 | 143.9B JPY (≈$978M) | 3 | 26 | |
| 423 | 475M USD | 3 | 22 | |
| 423 | 888M USD | 3 | 25 | |
| 423 | 1.1B USD | 3 | 26 | |
| 428 | 7.1B CNY (≈$993M) | 2 | 27 | |
| 428 | 3.5B HKD (≈$451M) | 2 | 51 | |
| 428 | 5.1B CNY (≈$709M) | 2 | 12 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score